Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Iptacopan in C3 Glomerulopathy
NCT03832114Phase 2Completed
- Sponsor
- Novartis
- Start
- Feb 2019
- Primary completion
- Apr 2021
- Modality
- Small Molecules
- Countries
- 6
01
Overview
Phase 2, open-label trial of Iptacopan in Complement 3 glomerulopathy (C3G) (2 cohorts), sponsored by Novartis. Primary endpoints: Urine Protein to Creatinine Ratio at 12 weeks and C3 Deposit Score at 12 weeks. Started Feb 2019; status: completed.
02
Drugs
Iptacopan
03
Conditions
Complement 3 glomerulopathy (C3G)
Beyond the preview
Go deeper on NCT03832114.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03832114.